Skip to main content
Equibles
ASTH logo

ASTH · Astrana Health, Inc.

Track ASTH — free

Use ASTH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ASTH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$38.41 -0.20 (-0.52%) At close · Aug 27
Market Cap
$2.15B
Shares
55.74M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$38.41 Open$38.27 Day$37.53–38.59 52W close$18.16–49.81 Avg vol 30d511K Short int3.2M · 5.7% float · 5.6d Short vol74% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 18, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +24%
      above
      Price vs 50-day avg −7%
      below
      RSI (14) 48
      neutral
      MACD trend Positive
      52-week position 64%
      mid-range
      Momentum
      relative strength
      Very Strong
      1-month return +5%
      trailing
      6-month return +54%
      trailing
      YTD return +55%
      this year
      Relative strength +40%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $41 › 200d $31 — 50d above 200d
      Institutional flow Accumulating
      +22% holders QoQ · +58 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      5.71% of float · ▲ +12.6% MoM · 5.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      209 holders — near 3-yr high, broad support
      Squeeze score 65
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +46%
      Y/Y
      Gross margin 0%
      contracting
      EPS growth −49%
      Y/Y
      Free cash flow $104.5M
      Valuation P/E 47.1
      rich
      Buyback $100.0M
      authorized
      Balance sheet $609.3M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 67%
      annualized · 1-yr
      Max drawdown −46%
      past year
      ATR 5.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 5 of last 6
      Latest guidance · from the 8-K filed Mar 2, 2026
      Year Ending December 31, 2026
      Net income $54M – $74M
      EBITDA $208M – $238M
      2026
      Net Income $54M – $74M
      Interest expense $51M – $55M
      Provision for income taxes $38M – $44M
      Depreciation and amortization $65M
      EBITDA $208M – $238M
      Income from equity method investments $-4M
      Other, net $7M
      Stock-based compensation $39M
      Prior guidance period ended · from the 8-K filed Jul 2, 2025
      Total revenue · full-year 2025 $3.1B – $3.3B
      Adjusted EBITDA · full-year 2025 $215M – $225M
      Guided vs delivered · last 6 settled
      Total revenue full-year 2025
      guided $3.1B – $3.3B
      $3.18B In line
      Revenue 2024 full-year
      guided $1.65B – $1.85B
      $2.03B Beat +16.3%
      Gap earnings per diluted share 2024 full-year
      guided $1.28 – $1.52
      $0.90 Miss −35.7%
      Revenue full year
      guided $1.34B – $1.39B
      $1.39B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +24% Bullish
      Price vs 50-day avg
      −7% Bearish
      RSI (14)
      48 Neutral
      MACD trend
      Positive Bullish
      52-week position
      64% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $41 › 200d $31 — 50d above 200d
      Institutional flow Accumulating
      +22% holders QoQ · +58 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      5.71% of float · ▲ +12.6% MoM · 5.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      209 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $18 Now $38 · 64% Range high $50
      vs 200-day avg +24% vs 50-day avg -7%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Care Partners members 1.2M Q2 2026 —
      Free cash flow non-GAAP $92.9M six months ended June 30, 2026 —
      gross shared savings $120.4M 2024 performance year —
      patients in value-based arrangements 1.5M Q2 2026 —
      patients supported in value-based care arrangements 1.5M current —
      providers supported 20,000 current —
      Texas agreement added approximately new Medicare Advantage professional-risk lives 3,000 current —
      Full-risk share of capitation revenue 80% Q1 2026 —
      Full-risk share of members 80% Q1 2026 —
      Revenue from full-risk arrangements 80% Q1 2026 —
      Remaining repurchase plan capacity $35.9M As of December 31, 2025 —
      Share repurchase program authorization (increased) $100M Year Ended December 31, 2025 —
      Shares repurchased 633,844 Three months ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ASTH
      Astrana Health, Inc.
      this stock
      		$2.15B +54.8% +45.9% 47.1 5.7%
      HCA
      HCA Healthcare, Inc.
      		 $93.03B -10.2% +7.1% 14.5 2.8%
      FSNUY
      Fresenius SE & Co. KGaA
      		 $30.21B -6.4% — — 0.0%
      THC
      Tenet Healthcare Corp
      		 $22.08B +34.7% +0.9% 10.6 3.1%
      FMS
      Fresenius Medical Care AG
      		 $12.38B -2.3% +5.9% — 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      209
      % held
      57.8%
      Net QoQ
      +2.0M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      228
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.2M
      Days to cover
      5.6d
      Change
      +357.4K sh
      View
      Short Volume
      Short vol %
      74%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      287
      Value
      $11.8K
      As of
      Jul 24, 2026
      View
      Off-Exchange
      Off-exchange %
      36.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Judy Chu
      Amount
      $100.0K–$250.0K
      Traded
      Aug 19, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $3.2B
      Net income (FY)
      $22.5M
      EPS diluted
      $0.46
      View
      Buybacks
      Authorized
      $100.0M
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 10, 2026
      This year
      17
      View
      Exempt Offerings
      Offering
      $1.4M
      Filed
      Nov 21, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ASTH -0.9% +4.7% +54.2% +8.0% +54.8%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY -2.0% +0.8% +39.5% +4.8% +41.7%

      Capital returns

      Buyback program · as of Nov 6, 2023
      Authorized
      $100.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1083446 CUSIP 03763A207 13F (30d) 178 filings 177 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)